Features | Partner Sites | Information | LinkXpress
Sign In
GLOBETECH PUBLISHING LLC
GLOBETECH PUBLISHING LLC
PZ HTL SA

A Transcriptional Co-Repressor Protein Links Obesity to Breast Cancer Risk

By BiotechDaily International staff writers
Posted on 28 Feb 2013
Weight gain and high-carbohydrate diets increase risk of developing breast cancer due to the activity of the transcriptional co-repressor protein CtBP (C-terminal binding protein).

The CtBP protein family has gained wide scientific interest due to findings that identified its critical role in animal development and oncogenesis. These multifunctional proteins predominantly function as transcriptional co-repressors in the nucleus by recruiting various histone-modifying enzymes such as histone deacetylases, histone methylases, and a histone demethylase. They also perform several diverse cytosolic functions such as Golgi maintenance and in central nervous system synapses.

Investigators at the [US] National Cancer Institute (Bethesda, MD, USA) used advanced genomic techniques to profile levels of CtBP in breast cancer cells. They reported in the February 5, 2013, online edition of the journal Nature Communications that elevated levels of CtBP in patient tumors predicted shorter survival time.

A high level of CtBP was found to drive epithelial-to-mesenchymal transition, stem cell pathways, and genome instability. Depletion of CtBP or caloric restriction reversed gene repression and increased DNA repair. Several members of the CtBP-targeted gene network were selectively downregulated in aggressive breast cancer subtypes. This group included the BRCA1 tumor suppressor gene. Both CtBP promoter targeting and gene repression could be reversed by small molecule inhibition.

“Our new work suggests that targeting CtBP may provide a way of treating breast cancer and possibly preventing breast cancer,” said senior author Dr. Kevin Gardner, head of the transcription regulation section at the [US] National Cancer Institute. “Modifying diet and maintaining a healthy diet, combined with developing pharmacological ways of lessening CtBP activity may one day lead to a way to break the link between cancer and obesity. Research should continue to focus on the link between obesity, CtBP, and breast cancer. This will require more population-based studies and multidisciplinary teams of scientist to investigate these links.”

Related Links:

National Cancer Institute



BIOSIGMA S.R.L.
SLAS - Society for Laboratory Automation and Screening
RANDOX LABORATORIES
comments powered by Disqus

Channels

Drug Discovery

view channel

Omega 3 Found to Improve Behavior in Children with ADHD

Supplements of the fatty acids omega 3 and 6 can help children and adolescents who have a specific kind of have attention deficit hyperactivity disorder (ADHD). Moreover, these findings indicate that a customized cognitive training program can improve problem behavior in children with ADHD. Statistics show that 3%–6%... Read more

Biochemistry

view channel

Blocking Enzyme Switch Turns Off Tumor Growth in T-Cell Acute Lymphoblastic Leukemia

Researchers recently reported that blocking the action of an enzyme “switch” needed to activate tumor growth is emerging as a practical strategy for treating T-cell acute lymphoblastic leukemia. An estimated 25% of the 500 US adolescents and young adults diagnosed yearly with this aggressive disease fail to respond to... Read more

Lab Technologies

view channel

e-Incubator Technology Provides Real-Time Imaging of Bioengineered Tissues in a Controlled Unit

A new e-incubator, an innovative miniature incubator that is compatible with magnetic resonance imaging (MRI), enables scientists to grow tissue-engineered constructs under a controlled setting and to study their growth and development in real time without risk of contamination or damage. Offering the potential to test... Read more

Business

view channel

Two Industry Partnerships Initiated to Fuel Neuroscience Research

Faster, more complex neural research is now attainable by combining technology from two research companies. Blackrock Microsystems, LLC (Salt Lake City, UT, USA), a developer of neuroscience research equipment, announced partnerships with two neuroscience research firms—PhenoSys, GmbH (Berlin, Germany) and NAN Instruments, Ltd.... Read more
 
Copyright © 2000-2014 Globetech Media. All rights reserved.